Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph phase_2
1
50%

Phase Distribution

0

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution1 total trials
Phase 2Efficacy & side effects
1(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

2

all time

Status Distribution
Active(1)
Other(1)

Detailed Status

Not yet recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
0
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 21 (100.0%)

Trials by Status

not_yet_recruiting150%
unknown150%

Recent Activity

0 active trials
Showing 2 of 2
not_yet_recruitingphase_2

One and Two Doses of Oxfendazole Versus a Schedule of Two Doses of Triclabendazole in Chronic Fascioliasis

NCT06367361
unknown

Compassionate Use of Triclabendazole for the Treatment of Parasites (Prior to FDA Approval; Expanded Access Program)

NCT01931085

Clinical Trials (2)

Showing 2 of 2 trials
NCT06367361Phase 2

One and Two Doses of Oxfendazole Versus a Schedule of Two Doses of Triclabendazole in Chronic Fascioliasis

Not Yet Recruiting
NCT01931085

Compassionate Use of Triclabendazole for the Treatment of Parasites (Prior to FDA Approval; Expanded Access Program)

Unknown

All 2 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
2